Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3001 to 3050 of 8238 results

  1. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    Page 1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at moderately increased risk

  2. Diabetes: annual care processes (IND10)

    This indicator covers the proportion of adults with diabetes who have received all 9 basic care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG13

  3. NICE glossary

    The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.

  4. Cardiovascular disease prevention: cardiovascular risk assessment for people newly diagnosed with hypertension or T2DM (IND161)

    This indicator covers the percentage of patients aged between 25 and 84 years with a new diagnosis of hypertension or type 2 diabetes, recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a consultation for full formal cardiovascular disease risk assessment between 3 months before or 3 months after date of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM132

  5. Cardiovascular disease prevention: cardiovascular risk assessment for people with bipolar, schizophrenia or other psychoses (IND150)

    This indicator covers the percentage of patients aged between 25 and 84 years with schizophrenia, bipolar affective disorder and other psychoses (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a full formal cardiovascular disease risk assessment performed in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM120

  6. Diabetes: CVD risk assessment (IND181)

    This indicator covers the percentage of patients aged between 25 and 84 years, with type 2 diabetes, without moderate or severe frailty, not currently treated with a statin, who have had a consultation for a full formal cardiovascular disease risk assessment in the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM160

  7. Rheumatoid arthritis: fracture risk assessment (IND109)

    This indicator covers the percentage of patients aged 50 to 90 years with rheumatoid arthritis who have had an assessment of fracture risk using a risk assessment tool adjusted for RA in the preceding 27 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM57

  8. Healthcare professionals - shaping our work

    Healthcare professionals - shaping our work A wide range of healthcare professionals, including primary care colleagues, work with NICE to develop

  9. In consultation

    See a complete list of indicators currently in consultation. Our indicators measure outcomes that reflect the quality of care or processes.

  10. Kidney conditions: CKD and blood pressure when ACR 70 or more (IND264)

    This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 125/75 mmHg if using ambulatory or home monitoring, or less than 130/80 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM248.

  11. Stakeholder registration: guidelines, quality standards and indicators

    How to register as a stakeholder to help us develop guidelines, quality standards and indicators.

  12. Our committees

    NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.

  13. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  14. Join our people and communities network

    Join NICE's people and communities network

  15. Making a positive impact: people and communities network case studies

    Making a positive impact: NICE people and communities network case studies

  16. Involving you in the development of our guidance

    Involving you in the development of NICE guidance.

  17. Study NICE and LSE's Executive MSc Healthcare Decision-Making

    Study NICE and LSE's Executive MSc Healthcare Decision-Making

  18. GPs and primary care

    GPs help to bring a primary care perspective to the guidance that we produce.

  19. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  20. Contributing to the development of our guidelines

    We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.

  21. NICE voluntary and community sector forum

    Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.

  22. Getting involved as someone with lived experience

    We want you to help NICE to develop our guidance for NHS and care services.

  23. Getting involved as a voluntary and community sector organisation

    Getting involved with NICE as a voluntary and community sector organisation

  24. Topic engagement

    Home Get involved Help develop quality standards...

  25. Support a quality standard

    Home Get involved Help develop quality standards...

  26. Quality standard consultations

    Home Get involved Help develop quality standards...

  27. Help implement NICE guidance

    Home Get involved...

  28. Help develop quality standards

    Home Get involved...

  29. Payments and expenses

    Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.

  30. Diabetes: IFCC-HbA1c 75mmol/mol or less (IND136)

    This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.

  31. Contraception: advice for people with bipolar, schizophrenia or other psychoses (IND124)

    This indicator covers the percentage of women with schizophrenia, bipolar affective disorder or other psychoses under the age of 45 years who have been given information and advice in the previous 12 months about pregnancy, conception or contraception tailored to their pregnancy and contraceptive intentions. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM78

  32. Public health advisory committee E members

    Details of the chair and core members of public health advisory committee E.

  33. Public health advisory committee F members

    Details about the chair and core members of NICE public health advisory committee F.

  34. NICE committee meetings

    NICE public committee meetings supports our commitment to having processes in place that are rigorous, open, and transparent.

  35. Public health advisory committees

    The standing committees were responsible for the development of our public health guidance.

  36. Public health advisory committee C members

    Details of the chair and core members of the public health advisory committee.

  37. Register your organisation as a stakeholder

    Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.

  38. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for stress urinary incontinence – Options for women referred to specialist centres

    Name: Consultant: (or affix hospital sticker) Patient decision aid Options for women referred to specialist centres Treating complications from mesh...

  39. Stroke and transient ischaemic attack in over 16s. Patient decision aid on decompressive hemicraniectomy surgery in people over 60

    1 Stroke: decompressive hemicraniectomy surgery in people over 60 Patient decision aid What are the pros and cons of decompressive hemicraniectomy?...

  40. Weight management: advice for people living with overweight (18 to 39 years) (IND319)

    This indicator covers the percentage of patients aged 18 to 39 years with a BMI of 23 kg/m2 to 27.4 kg/m2 (or 25 kg/m2 to 29.9 kg/m2 if ethnicity is recorded as White) in the preceding 12 months who have been given weight management advice within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  41. Infections: scoring tools for sore throat (IND323)

    This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  42. Kidney conditions: CKD and SGLT2 inhibitors (IND322)

    This indicator covers the percentage of patients on the CKD register and currently treated with an angiotensin receptor blocker (ARB) or an ACE inhibitor (unless these are contraindicated) who are also treated with an SGLT-2 inhibitor if they have: no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2, or no type 2 diabetes and an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2 and a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  43. Screening: cervical (25 to 64 years) (IND321)

    This indicator covers the percentage of women eligible for cervical screening and aged 25 to 64 years at end of the period reported whose notes record that an adequate cervical screening test has been performed in the previous 5.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  44. Weight management: BMI recording (long term conditions) (IND320)

    This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  45. Heart failure: ejection fraction category (IND318)

    This indicator covers the percentage of patients with a diagnosis of heart failure on or after 1 April 2026 who have a recorded ejection fraction category (reduced, mildly reduced, or preserved). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  46. Heart failure: 4 pillars (HFrEF) (IND317)

    This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  47. Asthma: MART (higher risk patients) (IND316)

    This indicator covers the percentage of patients with asthma on the register aged 12 years or over with a risk factor for poor outcomes who are prescribed maintenance and reliever therapy (MART) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  48. Asthma: annual review (higher risk patients) (IND315)

    This indicator covers the percentage of patients with asthma on the register with a risk factor for poor outcomes, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  49. Healthy start vitamins: special report on cost effectiveness (ECD5)

    This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering

  50. Accessibility changes: notes for developers (ECD6)

    This document summarises the most common accessibility changes NICE is making in guidelines, and why